Result of AGM
01 July 2026
Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease and ovarian cancer, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.
A copy of the voting results can be found on the website later today here.
For more information visit www.genincode.com
Enquiries:
| GENinCode Plc | www.genincode.com or via Walbrook PR |
| Matthew Walls, CEO | |
| Paul Foulger, CFO | |
| Cavendish Capital Markets Limited | Tel: +44 (0)20 7397 8900 |
| Giles Balleny / Trisyia Jamaludin (Corporate Finance) | |
| Harriet Ward (Corporate Broking) Nigel Birks (Specialist Sales) | |
| Walbrook PR Limited Anna Dunphy |
Tel: 020 7933 8780 or genincode@walbrookpr.com |
About GENinCode:
GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.
GENinCode operates business units in the UK, Europe through GENinCode S.L.U, and in the United States through GENinCode U.S. Inc.
GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict cardiovascular disease.